DAPSA | PASDAS | ASDAS | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total pSpA Population, n = 191 | pSpA Without PsO, n = 49 | pSpA With PsO, n = 142 | Total pSpA Population, n = 139 | pSpA Without PsO, n = 42 | pSpAWith PsO, n = 97 | Total pSpA Population, n = 279 | pSpA Without PsO, n = 82 | pSpAWith PsO, n= 197 | ||||||||||
Outcome Measure | rs | Hypothesis | rs | Hypothesis | rs | Hypothesis | rs | Hypothesis | rs | Hypothesis | rs | Hypothesis | rs | Hypothesis | rs | Hypothesis | rs | Hypothesis |
Disease activity | ||||||||||||||||||
DAPSA | NA | NA | NA | 0.91* | – H | 0.85* | + | 0.90* | – H | 0.80* | + | 0.79* | + | 0.89* | + | |||
PASDAS | 0.92* | - H | 0.85* | + | 0.91* | - H | NA | NA | NA | 0.84* | + | 0.80* | + | 0.83* | + | |||
ASDAS | 0.81* | + | 0.77* | + | 0.80* | + | 0.85* | + | 0.81* | + | 0.84* | + | NA | NA | NA | |||
BASDAIa | 0.76* | + | 0.73* | + | 0.76* | + | 0.78* | + | 0.67* | - L | 0.80* | + | 0.85* | 0.83* | 0.84* | |||
PtGAa,b,c | 0.89* | 0.87* | 0.89* | 0.92* | 0.88* | 0.91* | 0.82* | 0.79* | 0.79* | |||||||||
VAS painb | 0.89* | 0.86* | 0.90* | 0.74* | + | 0.71* | + | 0.74* | + | 0.69* | - L | 0.63* | - L | 0.69* | - L | |||
PGAc | 0.61* | + | 0.61* | + | 0.60* | + | 0.81* | 0.76* | 0.80* | 0.49* | - L | 0.46* | - L | 0.48* | - L | |||
CRPa,b,c | 0.19* | 0.33* | 0.13 | 0.15 | 0.25 | 0.12 | 0.48* | 0.56* | 0.44* | |||||||||
PsO BSA | –0.04 | NA | 0.01 | - L | –0.08 | NA | 0.00 | - L | 0.01 | NA | 0.14 | - L | ||||||
TJC68b,c | 0.67* | 0.75* | 0.67* | 0.52* | 0.48* | 0.58* | 0.39* | + | 0.35* | + | 0.44* | + | ||||||
SJC66b,c | 0.46* | 0.34 | 0.51* | 0.43* | 0.27 | 0.50* | 0.19* | + | –0.00 | + | 0.28* | + | ||||||
LEIc | 0.12 | + | 0.18 | + | 0.07 | + | 0.10 | 0.17 | 0.05 | 0.11 | + | 0.15 | + | 0.09 | + | |||
Dactylitis countc | 0.22 | + | ND | 0.26* | + | 0.19* | ND | 0.23* | 0.08 | + | ND | 0.12 | + | |||||
Physical function and health impact | ||||||||||||||||||
HAQ-S | 0.59* | + | 0.62* | + | 0.56* | + | 0.68* | + | 0.73* | - H | 0.65* | + | 0.63* | + | 0.65* | + | 0.60* | + |
ASAS HI | 0.67* | + | 0.57* | + | 0.67* | + | 0.68* | + | 0.60* | + | 0.68* | + | 0.63* | + | 0.64* | + | 0.57* | + |
HRQOL | ||||||||||||||||||
EQ-5D | –0.69* | + | –0.65* | + | –0.69* | + | –0.50* | + | –0.40* | + | –0.53* | + | –0.62* | + | –0.64* | + | –0.60* | + |
SF-36 MCS | –0.30* | + | –0.31* | + | –0.28* | - L | –0.15 | - L | –0.25 | - L | –0.13 | - L | –0.33* | + | –0.53* | + | –0.24* | - L |
SF-36 PCSc | –0.65* | + | –0.67* | + | –0.64* | + | –0.76* | –0.82* | –0.72* | –0.67* | + | –0.69* | + | –0.64* | + |
Correlations: “+” indicates strength of correlation as hypothesized. “-” indicates strength of correlation was not as hypothesized. “L” indicates that the strength of correlation is lower than hypothesized; “H” indicates that strength of correlation is higher than hypothesized; “ND” indicates that correlation could not be calculated as SD was zero. Individual components of the DAPSA, PASDAS, and ASDAS were not included in the calculation of the frequency of confirmed hypotheses for concurrent validity.
↵aASDAS components.
↵bDAPSA components.
↵cPASDAS components.
↵* Correlation is statistically significant at the 0.05 level (2-tailed). ASAS HI: Assessment of SpondyloArthritis international Society Health Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; axSpA: axial spondyloarthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BSA: body surface area; CRP: C-reactive protein; DAPSA: Disease Activity Index for Psoriatic Arthritis; EQ-5D: EuroQol-5 Dimensions; HAQ-S: Health Assessment Questionnaire for the Spondyloarthropathies; HRQOL: health-related quality of life; LEI: Leeds Enthesitis Index; MCS: mental component summary score; NA: not applicable; NSAID: nonsteroidal antiinflammatory drug; PASDAS: Psoriatic Arthritis Disease Activity Score; PCS: physical component summary score; PGA: physician global assessment; PtGA: patient global assessment; PsO: psoriasis; pSpA: peripheral spondyloarthritis; SF-36: 36-item Short Form Health Survey; SJC66: swollen joint count in 66 joints; TJC68: tender joint count in 68 joints; VAS: visual analog scale.